Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic DermatitisLisa A. Beck, Ana B. Rossi, Michael J. Cork et al.|JID Innovations|2022Cited by 234
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)Andreas Wollenberg, Marius Ardeleanu, Eric L. Simpson et al.|British Journal of Dermatology|2019Cited by 142
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic DermatitisMark Boguniewicz, Marius Ardeleanu, Lisa A. Beck et al.|The Journal of Allergy and Clinical Immunology In Practice|2021Cited by 56
Dupilumab Reduction of IgE Levels and Probability of Atopic Dermatitis Flares – Analysis of A Randomized Placebo-Controlled 52-Week StudyBrian Kim, Sonya Cyr, Lisa A. Beck et al.|Journal of Allergy and Clinical Immunology|2024Cited by 6